Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.93
OPK's Cash to Debt is ranked higher than
62% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. OPK: 0.93 )
OPK' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 0.93

Equity to Asset 0.69
OPK's Equity to Asset is ranked higher than
75% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. OPK: 0.69 )
OPK' s 10-Year Equity to Asset Range
Min: -0.41   Max: 0.96
Current: 0.69

-0.41
0.96
F-Score: 3
Z-Score: 5.27
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -172.95
OPK's Operating margin (%) is ranked higher than
50% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. OPK: -172.95 )
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44   Max: -39.08
Current: -172.95

-31624.44
-39.08
Net-margin (%) -157.04
OPK's Net-margin (%) is ranked higher than
50% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. OPK: -157.04 )
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54   Max: -4.59
Current: -157.04

-44561.54
-4.59
ROE (%) -15.42
OPK's ROE (%) is ranked higher than
58% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. OPK: -15.42 )
OPK' s 10-Year ROE (%) Range
Min: -3194.35   Max: -1.4
Current: -15.42

-3194.35
-1.4
ROA (%) -10.03
OPK's ROA (%) is ranked higher than
60% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. OPK: -10.03 )
OPK' s 10-Year ROA (%) Range
Min: -1352.71   Max: -0.83
Current: -10.03

-1352.71
-0.83
ROC (Joel Greenblatt) (%) -839.70
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. OPK: -839.70 )
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130662.93   Max: -57.21
Current: -839.7

-130662.93
-57.21
Revenue Growth (%) 34.90
OPK's Revenue Growth (%) is ranked higher than
96% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. OPK: 34.90 )
OPK' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 135.1
Current: 34.9

0
135.1
EBITDA Growth (%) 91.30
OPK's EBITDA Growth (%) is ranked higher than
98% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. OPK: 91.30 )
OPK' s 10-Year EBITDA Growth (%) Range
Min: -75.7   Max: 171.4
Current: 91.3

-75.7
171.4
EPS Growth (%) 74.70
OPK's EPS Growth (%) is ranked higher than
98% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. OPK: 74.70 )
OPK' s 10-Year EPS Growth (%) Range
Min: -69.4   Max: 152.4
Current: 74.7

-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OPK Guru Trades in Q4 2013

Steven Cohen 46,194 sh (+58.2%)
Murray Stahl 97,806 sh (+23.33%)
George Soros 844,600 sh (+13.37%)
Mario Gabelli 15,000 sh (unchged)
Jim Simons Sold Out
» More
Q1 2014

OPK Guru Trades in Q1 2014

Paul Tudor Jones 12,253 sh (New)
George Soros 1,494,800 sh (+76.98%)
Murray Stahl 123,170 sh (+25.93%)
Mario Gabelli 15,000 sh (unchged)
Steven Cohen Sold Out
» More
Q2 2014

OPK Guru Trades in Q2 2014

Paul Tudor Jones 13,145 sh (+7.28%)
Murray Stahl 125,930 sh (+2.24%)
Mario Gabelli 15,000 sh (unchged)
George Soros 235,600 sh (-84.24%)
» More
Q3 2014

OPK Guru Trades in Q3 2014

Murray Stahl 138,935 sh (+10.33%)
George Soros 235,600 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 11,000 sh (-26.67%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-09-30 Reduce -26.67%$8.19 - $9.46 $ 9.468%11000
George Soros 2014-06-30 Reduce -84.24%0.12%$8.01 - $9.71 $ 9.468%235600
George Soros 2014-03-31 Add 76.98%0.06%$7.58 - $9.96 $ 9.468%1494800
George Soros 2013-09-30 New Buy0.07%$7.18 - $9.24 $ 9.4618%745000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

OPKO CEO Is Building A Pharma Powerhouse And Continuously Buying Shares
OPKO Health (OPK) has come to my attention because I noticed that the chairman and CEO, Dr. Phillip Frost, has been consistently showing up on the list of CEO buys at GuruFocus. As I look back at the history, he has been doing so for years. According to the Form 4 filed with the SEC, his is the beneficial owner of shares in his own name, his trust, and an LLC. Together he is the beneficial owner of 158.71 million out of the 412.91 million shares outstanding, representing about 38 percent of the shares. As of 6/19/14, his position is valued at $1.457 billion. Phillip Frost has had many successful investments in the past, could this be the next one? Read more...
Weekly CEO Buys Highlight: OPK, PAYC, CLMS, WINA, HBAN
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, AMRC, ENBL, ALLY, NEON
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, AMRC, CLMS, OILT, WMC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: KCG, OPK, HOLX, CLMS, TDC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, GE, CLMS, HELI, GAM
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: OPK, HELI, RSPP, CLMS
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 4.55
OPK's P/B is ranked higher than
70% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. OPK: 4.55 )
OPK' s 10-Year P/B Range
Min: 3.65   Max: 50.6
Current: 4.55

3.65
50.6
P/S 45.65
OPK's P/S is ranked higher than
52% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. OPK: 45.65 )
OPK' s 10-Year P/S Range
Min: 15.25   Max: 126.5
Current: 45.65

15.25
126.5
EV-to-EBIT -27.54
OPK's EV-to-EBIT is ranked lower than
57% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. OPK: -27.54 )
OPK' s 10-Year EV-to-EBIT Range
Min: -107   Max: -3.8
Current: -27.54

-107
-3.8
Current Ratio 2.12
OPK's Current Ratio is ranked higher than
65% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. OPK: 2.12 )
OPK' s 10-Year Current Ratio Range
Min: 0.88   Max: 415
Current: 2.12

0.88
415
Quick Ratio 1.91
OPK's Quick Ratio is ranked higher than
70% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. OPK: 1.91 )
OPK' s 10-Year Quick Ratio Range
Min: 0.48   Max: 415
Current: 1.91

0.48
415

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.76
OPK's Price/Tangible Book is ranked higher than
72% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. OPK: 6.76 )
OPK' s 10-Year Price/Tangible Book Range
Min: 0.35   Max: 481
Current: 6.76

0.35
481
Price/DCF (Projected) 27.82
OPK's Price/DCF (Projected) is ranked higher than
79% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. OPK: 27.82 )
OPK' s 10-Year Price/DCF (Projected) Range
Min: 7.16   Max: 236.67
Current: 27.82

7.16
236.67
Price/Median PS Value 1.31
OPK's Price/Median PS Value is ranked higher than
73% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. OPK: 1.31 )
OPK' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 9.95
Current: 1.31

0.32
9.95
Earnings Yield (Greenblatt) -3.60
OPK's Earnings Yield (Greenblatt) is ranked higher than
60% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. OPK: -3.60 )
OPK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -3.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Self-Made Billionaire Believes Drone Aviation Holding Corp. (DRNE) Will Be 2015's Best-Performing Dr Dec 16 2014 
Why Opko Health Is a Better Investment Than Apple Dec 02 2014 
Weekly CEO Buys Highlight: APD, SFXE, HTZ, OPK, TRUE Nov 26 2014 
Weekly CEO Buys Highlight: AM, UPLD, MEMP, X, OPK Nov 17 2014 
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Weekly CEO Buys Highlight: NRP, SFXE, OPK, EPE, OMN Oct 12 2014 
Highlight of This Week's Insider Buys Sep 30 2014 
Weekly CEO Buys Highlight: CREG, OPK, LDOS, HALL, ULTA Sep 21 2014 

More From Other Websites
Pfizer Partners With Young Little Known Biotech For Products With Huge Potential Value Dec 18 2014
Pfizer Ponies Up to Develop Long-acting Growth Hormone Dec 16 2014
Pfizer, OPKO Health partner on growth-hormone treatment Dec 15 2014
Opko Health Inks Pfizer License Pact Dec 15 2014
Pfizer, OPKO Health Partner on Growth-Hormone Treatment Dec 15 2014
Pfizer Licenses Opko's Long-Acting Growth Hormone Dec 15 2014
OPKO HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 15 2014
Cramer's Mad Dash: Twitter gets a lift Dec 15 2014
Opko Health Soars 13% On Pfizer hGh-CTP News Dec 15 2014
OPKO and Pfizer Enter into Global Agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP) Dec 15 2014
OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting Human Growth Hormone (hGH-CTP) Dec 15 2014
Tiger Media Announces Agreement to Acquire Interactive Data, LLC Dec 15 2014
OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
OPKO Health to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 03 2014
Stockpickers' Blues Nov 29 2014
Cocrystal Pharma and RFS Pharma Merge to Create Advanced Antiviral Development Organization Nov 25 2014
OPKO HEALTH, INC. Financials Nov 14 2014
OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference Nov 13 2014
OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference Nov 13 2014
OPKO Health to Present at the Jefferies 2014 Global Healthcare Conference Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK